Duality of Interest. D.P. is chief investigator and E.S. and J.A. are co-investigators for the LENS trial, which has received fenofibrate and matching placebo tablets from Mylan free of charge. R.R.H. reports research support from AstraZeneca, Bayer, and Merck Sharp & Dohme and personal fees from Anji Pharmacueticals, Bayer, Novartis, and Novo Nordisk. H.N.G. is medical advisor for the Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. D.P. conceived the study. R.R.H., L.L., and H.N.G. were investigators on contributing trials. D.P., E.S., R.L.C., and L.L. conducted the analyses. D.P. drafted the manuscript. D.P., E.S., R.R.H., R.L.C., L.L., H.N.G., and J.A. contributed critical intellectual content, made important revisions to the manuscript, and contributed to the discussion. D.P. is the guarantor of this work and, as such, had full access to all the data in this study and takes responsibility for the integrity of the data and accuracy of the data analysis.

Prior Presentation. Parts of this work were presented in abstract form at the IDF Virtual Congress 2021, 6–11 December 2021.